Equillium, Inc. (EQ)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Immuno-inflammatory Disorders Therapies	41.10M
Immuno-inflammatory Disorders Therapies Growth	13.89%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
United States	41.10M
United States Growth	13.89%